Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
control small interfering RNA + DANP
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Control small interfering RNA + DANP is an experimental negative control formulation used in the development of dual assembly nanoparticles (DANP) for RNA interference (RNAi) therapy. The DANP delivery system is engineered with an inner aqueous core composed of chitosan and a polyphosphate anion (such as tripolyphosphate) which encapsulates the siRNA payload, and an outer hydrophobic coat of polylactic acid (PLA) to provide sustained release and protection from nuclease degradation. This specific version contains a non-silencing "control" siRNA that lacks sequence homology to any known human mRNA, serving as a baseline to evaluate the delivery system's toxicity and to differentiate the gene-specific effects of therapeutic siRNAs (such as those targeting ZNF304). Developed primarily for research in ovarian carcinoma, the DANP platform aims to extend the duration of gene silencing in vivo compared to standard chitosan-based carriers.
- Other names
- control siRNA-loaded DANPDANP-siRNA (control)Control siRNA-DANP
Beyond the preview
Go deeper on control small interfering RNA + DANP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on control small interfering RNA + DANP.